drugset / Trial / NCT06858735
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2
Recruiting
60 enrolled
M.D. Anderson Cancer Center
AstraZeneca · collabVarian Medical Systems · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT.
Timeline
- Start
- 2025-06-10
- Primary completion
- 2028-11-19
- Completion
- 2030-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Background | Durvalumab | Monoclonal antibody | — | Intravenous |